Scientific deep-dive
Vyvanse, Adderall, and Stimulants for Weight: What the Evidence Shows (And Why Most of It Is Off-Label)
Vyvanse is FDA-approved for binge-eating disorder, not weight loss, and Adderall for ADHD and narcolepsy, not weight loss. Both are Schedule II. In BED trials Vyvanse 50 to 70 mg a day produced about 5 kg of weight loss as a secondary outcome.
Vyvanse (lisdexamfetamine) is the only FDA-approved medication for moderate-to-severe binge-eating disorder (BED) in adults. It is not approved for weight loss as a primary indication. Adderall (mixed amphetamine salts) is FDA-approved for ADHD and narcolepsy. It is also not approved for weight loss. Both are DEA Schedule II controlled substances with cardiovascular and psychiatric warnings. The published BED trial program (McElroy 2015 dose-finding[1], McElroy 2016 Phase 3 pivotals[2], Hudson 2017 maintenance[3], Grilo 2024 continuation [4]) is real and consistent: Vyvanse 50-70 mg/day produces approximately −5 kg weight loss as a secondary outcome alongside dramatic binge-frequency reductions. But that's the BED population — patients who meet DSM-5 BED criteria, not patients who occasionally overeat. Combining stimulants with a GLP-1 has zero RCT data and additive cardiovascular concerns. Here is the verified evidence.
The evidence, study by study
The McElroy 2015 dose-finding trial
McElroy and colleagues[1] randomized 259 adults with moderate-to-severe BED to lisdexamfetamine 30, 50, or 70 mg/day or placebo over 11 weeks (3-week titration plus 8-week maintenance). Primary endpoint: log-transformed binge-eating days per week.
- 50 mg dose: significant binge-day reduction vs placebo (p=0.01)
- 70 mg dose: significant binge-day reduction vs placebo (p<0.001)
- 30 mg dose: no significant difference from placebo
4-week binge cessation rates: 50% on 70 mg, 42.2% on 50 mg, vs 21.3% on placebo. Weight loss as a secondary outcome:
- Placebo: −0.1 kg
- 30 mg: −3.1 kg
- 50 mg: −4.9 kg
- 70 mg: −4.9 kg
That weight loss is real and clinically meaningful, but it is the secondary endpoint of a BED trial, not a weight-loss trial. The 50 mg and 70 mg doses became the FDA-approved Vyvanse range for BED.
The 2016 pivotal Phase 3 trials
McElroy 2016[2] reported the two pivotal Phase 3 trials that supported the FDA approval. n=383 in Study 1 and n=390 in Study 2; 12 weeks total (3-week titration + 9-week maintenance) at 50 or 70 mg/day vs placebo.
- Study 1: Vyvanse reduced binge-eating days by −1.35 days/week more than placebo (p<0.001)
- Study 2: Vyvanse reduced binge-eating days by −1.66 days/week more than placebo (p<0.001)
Most common adverse events (≥10% of patients): dry mouth, insomnia, headache. Mean pulse rate increased 4.4-6.3 bpm in the active arms. The two trials together formed the basis for the FDA's January 30, 2015 approval of Vyvanse for moderate-to-severe BED in adults — the first and only FDA-approved BED medication.
The Hudson 2017 maintenance trial
Hudson 2017[3] answered the durability question. 418 patients entered a 12-week open-label optimization phase on Vyvanse; 275 completed and were randomized to continue Vyvanse vs switch to placebo for 26 additional weeks of double-blind maintenance.
- BED relapse over 6 months: 3.7% on Vyvanse (5/136 patients) vs 32.1% on placebo (42/131 patients)
- Hazard ratio for relapse: 0.09 (95% CI 0.04-0.23)
The 6-month relapse data are striking. Vyvanse essentially eliminated relapse over 6 months in patients who had responded acutely — a much bigger maintenance effect than the original dose-finding trial would have predicted. This is the strongest single piece of evidence supporting long-term Vyvanse use in BED.
The Grilo 2024 continuation trial
Grilo 2024[4] in Psychological Medicine (n=61) tested Vyvanse maintenance in patients who had responded to acute LDX with or without CBT. Smaller and more recent than the Hudson trial, with mixed-acute-treatment responders. Outcomes:
- BED relapse: 10.0% on LDX vs 17.9% on placebo (not statistically different)
- Weight change at 12-week maintenance: −2.3% LDX vs +2.2% placebo (statistically significant)
- Eating-disorder psychopathology stable on LDX, worsened on placebo
The Grilo trial tested maintenance among adults with BED and obesity who had responded to acute LDX alone or CBT plus LDX. Unlike Hudson 2017, Grilo found no significant difference from placebo in binge-eating relapse or remission; the separation was in weight (−2.3% vs +2.2%) and eating-disorder psychopathology.
BED prevalence and overlap with obesity
Patients sometimes assume BED is rare. It isn't. Two major epidemiology studies bound the prevalence:
Hudson 2007 (NCS-R)[5] reported from the National Comorbidity Survey Replication (n=9,282 US community respondents):
- Lifetime BED prevalence: 3.5% in women, 2.0% in men (overall ~2.8%)
- Strong association with severe obesity (BMI ≥40)
- Common comorbidity with mood, anxiety, and substance use disorders
Kessler 2013[6] in 14-country WHO World Mental Health Surveys (n=24,124) reported a median country-level lifetime BED prevalence of 1.4% (interquartile range 0.8-1.9%) — somewhat lower than the US-only Hudson estimate. Both studies emphasized that fewer than half of people with BED ever receive treatment.
BED is a distinct DSM-5 disorder — recurrent binge episodes (≥1 per week for ≥3 months) with marked distress, eating much more rapidly than normal, eating until uncomfortably full, eating large amounts when not physically hungry, eating alone due to embarrassment, and feelings of disgust or guilt afterward. It is not the same as “I sometimes overeat” and it requires a clinical diagnosis. Vyvanse is approved for the diagnosis, not the behavior in isolation.
Vyvanse cardiovascular and psychiatric warnings
The FDA label[9] for Vyvanse carries a boxed warning for sudden death, myocardial infarction, and stroke. Specific concerns:
- Cardiovascular: mean systolic and diastolic BP increases of approximately 5-10 mmHg, mean resting HR increases of 4-6 bpm at therapeutic BED doses. Avoid in structural cardiac abnormalities, cardiomyopathy, coronary artery disease, and uncontrolled hypertension.
- Psychiatric: psychosis and mania risk, especially at higher doses; aggression, agitation, and paranoid ideation reported in a small proportion. Effects typically resolve 2-6 days after discontinuation.
- Seizure risk: lower than bupropion; ADHD stimulants are actually associated with lower seizure odds in adjusted analyses.
- Abuse and dependence: DEA Schedule II reflects high abuse potential. Lisdexamfetamine is a prodrug (lower immediate-release peak than d-amphetamine or methamphetamine), which somewhat reduces the abuse liability profile vs Adderall.
Adderall and weight loss
Adderall (mixed amphetamine salts) is FDA-approved for ADHD and narcolepsy. It is not approved for weight loss in any population, and any use for weight loss is off-label and not evidence-based. The pediatric ADHD literature documents weight effects (typically −1 to −2 kg in children on long-term stimulant treatment), but no RCT has tested Adderall specifically for weight loss in adults. The DEA explicitly warns that weight lost on stimulants is regained upon cessation and that misuse of prescription stimulants for cosmetic weight loss contributes to stimulant use disorder risk.
Some obesity-medicine specialists prescribe Adderall off-label in patients with comorbid ADHD and obesity, with the rationale that treating the ADHD may improve dietary control and impulse regulation. This is a defensible clinical decision for patients with documented ADHD; it is not an evidence-based weight-loss intervention for non-ADHD patients.
Combining stimulants with a GLP-1
There is no published RCT on combining Vyvanse or Adderall with a GLP-1 receptor agonist. The closest precedent is the phentermine + GLP-1 literature, which we cover in our existing phentermine + GLP-1 article. People already taking a stimulant for ADHD face the same stacking questions from the other side when pairing a GLP-1 with Adderall, Vyvanse or Ritalin. Theoretical concerns:
- Additive cardiovascular effects. Both drug classes elevate resting heart rate and blood pressure. The combination warrants baseline ECG, baseline BP, and ongoing monitoring.
- Additive appetite suppression. GLP-1s suppress appetite via vagal and CNS GLP-1R activation; stimulants suppress appetite via catecholaminergic mechanisms. The combination can produce excessive nausea, vomiting, gastric dysmotility, or insufficient caloric intake.
- Drug interaction risk. Amphetamines plus GLP-1 agonists on sympathomimetic tone is theoretically concerning, though no PK interaction is documented in the GLP-1 labels.
- Patient selection matters. A patient on Vyvanse for documented BED who develops obesity is a legitimate candidate for adding a GLP-1 with cardiovascular oversight. A patient on Adderall off-label for weight loss who wants to add a GLP-1 is in a much weaker evidence-and-safety position.
Vyvanse cost and access in 2026
Vyvanse went generic on August 25, 2023, when first generic approvals were granted to Actavis Elizabeth, Teva, Aurobindo, and others after the compound patent expired (February 24, 2023) plus a 6-month pediatric exclusivity extension. Prices have dropped 50-85% from the brand peak. As of November 2026, generic lisdexamfetamine is fillable at most US pharmacies, but the live FDA Drug Shortages Database still lists the “Lisdexamfetamine Dimesylate Capsule” shortage as current (first posted July 14, 2023). Of the 108 lisdexamfetamine presentations listed, 75 report “Available” and 33 report “Limited Availability,” spread across five generic manufacturers (Hikma, Sun, Elite, Rhodes, and Solco). That is a narrower situation than Adderall's, where some strengths report “Unavailable,” but it means a specific strength from a specific manufacturer may need a pharmacy-to-pharmacy check.
Adderall, by contrast, has been in active shortage since late 2022 due to API delays, manufacturer discontinuations (Mylan, Zydus discontinued IR tablets), and DEA quota constraints. The DEA increased the 2025 amphetamine APQ from 21.2M to 26.5M grams; the 2026 APQ is 24.2M grams (~14% above the originally proposed level, per the DEA's January 2026 final order). Re-verified directly against the live FDA Drug Shortages Database in November 2026: the generic mixed amphetamine-salts (Adderall) tablet shortage is still listed as current (first posted October 12, 2022). Of the 73 listed presentations, 44 report “Available,” 10 “Limited Availability,” and 19 “Unavailable,” with manufacturer recovery estimates running from November 2026 to April 2027 (several listed as TBD), so the shortage has not resolved. This shortage has indirectly increased Vyvanse and other stimulant prescribing as substitutes.
Both drugs are DEA Schedule II controlled substances:
- Written prescription required (no electronic auto-refills in most states)
- No refills allowed; new prescription required each fill
- Some states require triplicate or state-specific forms
- Pharmacy verification of prescriber DEA registration
Off-label vs on-label clarity
For a patient or clinician trying to make sense of all this:
- Vyvanse for diagnosed moderate-severe BED: on-label, evidence-based, FDA-approved. Weight loss is a documented secondary effect.
- Vyvanse for weight loss without BED: off-label, not evidence-based, not recommended.
- Adderall for ADHD: on-label, established. Weight loss is a secondary effect.
- Adderall for weight loss: off-label, not evidence-based, not recommended.
- Phentermine for weight loss: on-label, short-term (12 weeks). See our existing phentermine + GLP-1 article.
- Qsymia (phentermine + topiramate): on-label, chronic weight management. See our Topamax / Qsymia article.
Magnitude comparison vs GLP-1s
Magnitude comparison
Total body-weight reduction at trial endpoint — Vyvanse in BED, typical ADHD-stimulant weight effect, phentermine (closest FDA-approved weight-loss comparator), and FDA-approved GLP-1s. Sources: McElroy 2015 LDX dose-finding (BED), STEP-1, SURMOUNT-1.[1][7][8]
- Adderall — typical adult ADHD trial weight effect1.5 % TBWL0 RCTs for weight loss; effect is incidental, not approved
- Vyvanse 50–70 mg — McElroy 2015 BED trial, 11 wk5.0 % TBWL−4.9 kg secondary outcome in BED; not approved for weight loss
- Phentermine 30 mg — short-term monotherapy, 12 wk5.0 % TBWLFDA-approved for short-term weight management
- Wegovy — semaglutide 2.4 mg (STEP-1, 68 wk)14.9 % TBWL
- Zepbound — tirzepatide 15 mg (SURMOUNT-1, 72 wk)20.9 % TBWL
Read the chart honestly: even Vyvanse's on-label BED weight effect (~−4.9 kg, secondary outcome) sits well below the FDA-approved GLP-1 obesity magnitudes (Wegovy −14.9% over 68 weeks[7], Zepbound −20.9% over 72 weeks[8]). Adderall has no RCT-grade weight-loss signal in adults at all. Phentermine monotherapy — the closest FDA-approved stimulant-class weight-loss agent — is roughly in the Vyvanse-BED range at ~5% TBWL but is approved only for short-term use (12 weeks). The takeaway: no stimulant in this chart is in the GLP-1 magnitude range, and only one (phentermine) carries an FDA weight-loss indication at all.
Bottom line
- Vyvanse is FDA-approved for moderate-severe BED in adults, NOT weight loss. Approval based on McElroy 2015 dose-finding, McElroy 2016 pivotal Phase 3 trials, and Hudson 2017 maintenance trial.
- Vyvanse weight effect at 50-70 mg in BED trials: ~−5 kg, secondary outcome.
- BED lifetime prevalence: ~2.8% (Hudson 2007 NCS-R) to a median 1.4% across 14 countries (Kessler 2013 WHO). Strongly associated with obesity but distinct from occasional overeating.
- Adderall has zero FDA approval for weight loss; off-label use is not evidence-based and not recommended.
- Both drugs are DEA Schedule II with cardiovascular and psychiatric warnings.
- No RCT data on stimulant + GLP-1 combinations. Theoretical additive cardiovascular and appetite-suppression concerns. Cite the phentermine + GLP-1 article as the closest analog.
- Vyvanse generic launched August 25, 2023; substantial price reductions. Adderall remains in shortage as of November 2026, re-verified against the live FDA Drug Shortages Database.
Both are DEA Schedule II controlled substances with cardiovascular and psychiatric risks. Diagnosed binge-eating disorder is the only FDA-approved Vyvanse indication for adults; off-label use for weight loss alone is not evidence-based and warrants extreme caution. Decisions about stimulant therapy for any indication should be made with a qualified prescribing clinician (typically psychiatry or specialized obesity medicine) who can document the diagnosis, monitor cardiovascular and psychiatric status, and manage controlled-substance prescribing safely.
Frequently Asked Questions
References
- 1.McElroy SL, Hudson JI, Mitchell JE, Wilfley D, Ferreira-Cornwell MC, Gao J, Wang J, Whitaker T, Jonas J, Gasior M. Efficacy and Safety of Lisdexamfetamine for Treatment of Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2015. PMID: 25587645.
- 2.McElroy SL, Hudson J, Ferreira-Cornwell MC, Radewonuk J, Whitaker T, Gasior M. Lisdexamfetamine Dimesylate for Adults with Moderate to Severe Binge Eating Disorder: Results of Two Pivotal Phase 3 Randomized Controlled Trials. Neuropsychopharmacology. 2016. PMID: 26346638.
- 3.Hudson JI, McElroy SL, Ferreira-Cornwell MC, Radewonuk J, Gasior M. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017. PMID: 28700805.
- 4.Grilo CM, Lydecker JA, Gueorguieva R. Lisdexamfetamine maintenance treatment for binge-eating disorder: a randomized double-blind placebo-controlled trial. Psychol Med. 2024. PMID: 39258475.
- 5.Hudson JI, Hiripi E, Pope HG Jr, Kessler RC. The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication. Biol Psychiatry. 2007. PMID: 16815322.
- 6.Kessler RC, Berglund PA, Chiu WT, Deitz AC, Hudson JI, Shahly V, Aguilar-Gaxiola S, Alonso J, Angermeyer MC, Benjet C, Bruffaerts R, de Girolamo G, de Graaf R, Maria Haro J, Kovess-Masfety V, O'Neill S, Posada-Villa J, Sasu C, Scott K, Viana MC, Xavier M. The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys. Biol Psychiatry. 2013. PMID: 23290497.
- 7.Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. PMID: 33567185.
- 8.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. PMID: 35658024.
- 9.Takeda Pharmaceuticals. VYVANSE (lisdexamfetamine dimesylate) capsules — US Prescribing Information including BED indication, cardiovascular and psychiatric warnings, and DEA Schedule II classification. FDA Approved Labeling. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/021977s055lbl.pdf
- 10.U.S. Food and Drug Administration. FDA Drug Shortages Database — Amphetamine Aspartate Monohydrate, Amphetamine Sulfate, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate Tablet (generic Adderall); and Lisdexamfetamine Dimesylate Capsule (generic Vyvanse) active-ingredient shortage listings, as of November 2026. FDA Drug Shortages Database. 2026. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
Related research
GLP-1 + Adderall, Vyvanse, or Ritalin: The Stacking Evidence
Stimulants suppress appetite; GLP-1s also suppress appetite. Stacking them creates a compounded caloric-deficit risk and may worsen tachycardia. We review the FDA labels for Adderall, Vyvanse, and Ritalin, plus the bupropion-naltrexone Contrave comparison.
12 min read
GLP-1 for Binge Eating Disorder: Vyvanse Comparison and Stacking Evidence
Vyvanse is the only FDA-approved drug for BED, but GLP-1 receptor agonists show meaningful reduction in binge episodes per published case series. We review the McElroy 2015 / Hudson 2017 Vyvanse trials, the GLP-1 mechanism, and the practical psychiatric pathway.
11 min read
Does Vyvanse Cause Weight Loss? Honest Evidence Review
Yes — Vyvanse (lisdexamfetamine) causes modest weight loss via d-amphetamine release, but the FDA label explicitly states it is not indicated for weight loss. Schedule II with Boxed Warning for abuse; FDA-approved only for ADHD and binge eating disorder.
11 min read
“Same Molecule” Is Not the Same Product: Compounded GLP-1 Impurities
“It is the same molecule” is true and incomplete. A medicine is a formulation, and purity, degradation and immunogenicity are properties of a specific preparation from a specific facility — questions that have now been studied directly rather than assumed away.
7 min read
2026 Obesity Medication Guidelines: ACP, Obesity Societies and VA/DoD Compared
US guidelines from 2025–2026 rank semaglutide and tirzepatide as the preferred weight-loss medicines, support long-term use and drop the 'diet first' rule. What the ACP, TOS/OMA/OAC and VA/DoD each recommend, where they differ, and what it means for coverage.
8 min read
5-HTP for Appetite & Weight Loss: The Evidence
Two small 1990s trials (Cangiano) found 5-HTP cut caloric intake and produced modest weight loss, and the serotonin-satiety mechanism is real — but there's no large modern RCT, plus a serotonin-syndrome risk with SSRIs and a contaminant history. A mixed verdict.
9 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Read full review →Pricing Compare
Get started →Found
Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Read full review →Pricing Compare
Get started →Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →Pricing Compare
Get started →